Gansu Duyiwei signs deal to develop, commercialize APX004 in China
APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases. As per the agreement, GDBP will have an exclusive license
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.